Compare, Analyse Novartis with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs MYLAN (US) - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   MYLAN
EQUITY SHARE DATA
    NOVARTIS
Mar-19
MYLAN
Dec-18
NOVARTIS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9803,549-   
Low Rs6001,953-   
Sales per share (Unadj.) Rs198.71,633.1-  
Earnings per share (Unadj.) Rs21.044.3-  
Cash flow per share (Unadj.) Rs22.3350.1-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs307.51,766.7-  
Shares outstanding (eoy) m24.69514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.01.7 236.0%   
Avg P/E ratio x37.762.0 60.7%  
P/CF ratio (eoy) x35.57.9 451.8%  
Price / Book Value ratio x2.61.6 165.0%  
Dividend payout %47.70-   
Avg Mkt Cap Rs m19,5081,415,525 1.4%   
No. of employees `0000.635.0 1.7%   
Total wages/salary Rs m1,1710-   
Avg. sales/employee Rs Th8,445.424,006.2 35.2%   
Avg. wages/employee Rs Th2,015.70-   
Avg. net profit/employee Rs Th891.0651.9 136.7%   
INCOME DATA
Net Sales Rs m4,907840,217 0.6%  
Other income Rs m7830-   
Total revenues Rs m5,689840,217 0.7%   
Gross profit Rs m123217,417 0.1%  
Depreciation Rs m32157,322 0.0%   
Interest Rs m1640,412 0.0%   
Profit before tax Rs m85819,684 4.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m340-3,132 -10.9%   
Profit after tax Rs m51822,815 2.3%  
Gross profit margin %2.525.9 9.7%  
Effective tax rate %39.6-15.9 -249.2%   
Net profit margin %10.62.7 388.5%  
BALANCE SHEET DATA
Current assets Rs m8,055469,176 1.7%   
Current liabilities Rs m1,850342,081 0.5%   
Net working cap to sales %126.415.1 835.9%  
Current ratio x4.41.4 317.4%  
Inventory Days Days4584 53.9%  
Debtors Days Days3493 36.3%  
Net fixed assets Rs m150162,988 0.1%   
Share capital Rs m123447 27.6%   
"Free" reserves Rs m7,4690-   
Net worth Rs m7,592908,961 0.8%   
Long term debt Rs m0981,060 0.0%   
Total assets Rs m9,8242,438,187 0.4%  
Interest coverage x54.91.5 3,694.7%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.50.3 144.9%   
Return on assets %5.42.6 209.4%  
Return on equity %6.82.5 271.7%  
Return on capital %11.53.2 361.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,2690-   
CASH FLOW
From Operations Rs m-1,943174,597 -1.1%  
From Investments Rs m2,742-90,247 -3.0%  
From Financial Activity Rs m-298-81,338 0.4%  
Net Cashflow Rs m5011,446 34.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 74.56 Rs / USD

Compare NOVARTIS With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: TTK HEALTHCARE  PANACEA BIOTECH  J.B.CHEMICALS  SHASUN PHARMA  WYETH  



Today's Market

6 Reasons Why Sensex Plunged 1,708 Points Today(Closing)

Indian share markets witnessed huge selling pressure today as fears that the government could go for stricter lockdowns.

Related Views On News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market (Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers (Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

India's Revival: A Once-in-a-generation Wealth Making Opportunity
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

NOVARTIS SHARE PRICE


Apr 12, 2021 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NOVARTIS

NOVARTIS 5-YR ANALYSIS

COMPARE NOVARTIS WITH

FEATURED VIDEOS

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

Kalyan Jewellers IPO: An Honest View

More Featured Videos

MARKET STATS